國立虎尾科技大學 |

Preclinical Evaluation of Antimicrobial Nanodrugs

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Preclinical Evaluation of Antimicrobial Nanodrugs/ by Juan Bueno.
作者:	Bueno, Juan.
面頁冊數:	XI, 117 p. 25 illus., 24 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Plant Biochemistry. -
電子資源:	https://doi.org/10.1007/978-3-030-43855-5
ISBN:	9783030438555

Preclinical Evaluation of Antimicrobial Nanodrugs
Bueno, Juan.

Preclinical Evaluation of Antimicrobial Nanodrugs[electronic resource] /by Juan Bueno. - 1st ed. 2020. - XI, 117 p. 25 illus., 24 illus. in color.online resource. - Nanotechnology in the Life Sciences,2523-8027. - Nanotechnology in the Life Sciences,.

Preface -- 1. Antimicrobial screening, foundations and interpretation -- 2. Antimicrobial activity of nanomaterials, from selection to application -- 3. Synergy and antagonism, the criteria of the formulation -- 4. In vitro Nanotoxicity, towards the development of safe and effective treatments -- 5. ADMETox, bringing nanotechnology closer to Lipinski's rule of five -- 6. Antimicrobial nanotechnology in preventing the transmission of infectious disease -- 7. Nanotechnology in the discovery of new antimicrobial drugs: is a new scientific revolution possible? -- 8. Nanotechnology beyond the antibiosis -- Index. .

Translational medicine addresses the gap between research and the clinical application of new discoveries. To efficiently deliver new drugs to care centers, a preclinical evaluation, both in vitro and in vivo, is required to ensure that the most active and least toxic compounds are selected as well as to predict clinical outcome. Antimicrobial nanomedicines have been shown to have higher specificity in their therapeutic targets and the ability to serve as adjuvants, increasing the effectiveness of pre-existing immune compounds. The design and development of new standardized protocols for evaluating antimicrobial nanomedicines is needed for both the industry and clinical laboratory. These protocols must aim to evaluate laboratory activity and present models of pharmacokinetic-pharmacodynamic and toxicokinetic behavior that predict absorption and distribution. Likewise, these protocols must follow a theranostics approach, be able to detect promising formulations, diagnose the infectious disease, and determine the correct treatment to implement a personalized therapeutic behavior. Given the possibilities that nanotechnology offers, not updating to new screening platforms is inadequate as it prevents the correct application of discoveries, increasing the effect of the valley of death between innovations and their use. This book is structured to discuss the fundamentals taken into account for the design of robust, reproducible and automatable evaluation platforms. These vital platforms should enable the discovery of new medicines with which to face antimicrobial resistance (RAM), one of the great problems of our time.

ISBN: 9783030438555

Standard No.: 10.1007/978-3-030-43855-5doiSubjects--Topical Terms:

668758
Plant Biochemistry.

LC Class. No.: QR46

Dewey Class. No.: 616.9041

Preclinical Evaluation of Antimicrobial Nanodrugs
LDR:03676nam a22004095i 4500 001 1025798
003 DE-He213
005 20200702005616.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783030438555 $9 978-3-030-43855-5
024 7 $a 10.1007/978-3-030-43855-5 $2 doi
035 $a 978-3-030-43855-5
050 4 $a QR46
072 7 $a MMFM $2 bicssc
072 7 $a MED052000 $2 bisacsh
072 7 $a MKFM $2 thema
082 0 4 $a 616.9041 $2 23
100 1 $a Bueno, Juan. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1322120
245 1 0 $a Preclinical Evaluation of Antimicrobial Nanodrugs $h [electronic resource] / $c by Juan Bueno.
250 $a 1st ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a XI, 117 p. 25 illus., 24 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Nanotechnology in the Life Sciences, $x 2523-8027
505 0 $a Preface -- 1. Antimicrobial screening, foundations and interpretation -- 2. Antimicrobial activity of nanomaterials, from selection to application -- 3. Synergy and antagonism, the criteria of the formulation -- 4. In vitro Nanotoxicity, towards the development of safe and effective treatments -- 5. ADMETox, bringing nanotechnology closer to Lipinski's rule of five -- 6. Antimicrobial nanotechnology in preventing the transmission of infectious disease -- 7. Nanotechnology in the discovery of new antimicrobial drugs: is a new scientific revolution possible? -- 8. Nanotechnology beyond the antibiosis -- Index. .
520 $a Translational medicine addresses the gap between research and the clinical application of new discoveries. To efficiently deliver new drugs to care centers, a preclinical evaluation, both in vitro and in vivo, is required to ensure that the most active and least toxic compounds are selected as well as to predict clinical outcome. Antimicrobial nanomedicines have been shown to have higher specificity in their therapeutic targets and the ability to serve as adjuvants, increasing the effectiveness of pre-existing immune compounds. The design and development of new standardized protocols for evaluating antimicrobial nanomedicines is needed for both the industry and clinical laboratory. These protocols must aim to evaluate laboratory activity and present models of pharmacokinetic-pharmacodynamic and toxicokinetic behavior that predict absorption and distribution. Likewise, these protocols must follow a theranostics approach, be able to detect promising formulations, diagnose the infectious disease, and determine the correct treatment to implement a personalized therapeutic behavior. Given the possibilities that nanotechnology offers, not updating to new screening platforms is inadequate as it prevents the correct application of discoveries, increasing the effect of the valley of death between innovations and their use. This book is structured to discuss the fundamentals taken into account for the design of robust, reproducible and automatable evaluation platforms. These vital platforms should enable the discovery of new medicines with which to face antimicrobial resistance (RAM), one of the great problems of our time.
650 2 4 $a Plant Biochemistry. $3 668758
650 2 4 $a Plant Breeding/Biotechnology. $3 677715
650 2 4 $a Pharmaceutical Sciences/Technology. $3 768561
650 2 4 $a Microbial Genetics and Genomics. $3 668641
650 1 4 $a Medical Microbiology. $3 668401
650 0 $a Plant biochemistry. $3 1253547
650 0 $a Plant breeding. $3 568050
650 0 $a Pharmaceutical technology. $3 557391
650 0 $a Nanotechnology. $3 557660
650 0 $a Microbial genomics. $3 782637
650 0 $a Microbial genetics. $3 582864
650 0 $a Medical microbiology. $3 583124
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030438548
776 0 8 $i Printed edition: $z 9783030438562
776 0 8 $i Printed edition: $z 9783030438579
830 0 $a Nanotechnology in the Life Sciences, $x 2523-8027 $3 1281535
856 4 0 $u https://doi.org/10.1007/978-3-030-43855-5
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)